ENDRA Life Sciences Inc.
NDRA
$3.57
$0.1253.63%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 714.60K | 1.51M | 1.74M | 878.40K | 1.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51M | 2.23M | 2.78M | 1.46M | 3.13M |
| Operating Income | -1.51M | -2.23M | -2.78M | -1.46M | -3.13M |
| Income Before Tax | -2.35M | -2.23M | -2.78M | -1.46M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.35M | -2.23M | -2.78M | -1.46M | -3.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.35M | -2.23M | -2.78M | -1.46M | -3.10M |
| EBIT | -1.51M | -2.23M | -2.78M | -1.46M | -3.13M |
| EBITDA | -1.50M | -2.22M | -2.77M | -1.44M | -3.10M |
| EPS Basic | -9.54 | -142.99 | -- | -- | -- |
| Normalized Basic EPS | -5.96 | -89.37 | -- | -- | -- |
| EPS Diluted | -9.54 | -142.99 | -- | -- | -- |
| Normalized Diluted EPS | -5.96 | -89.37 | -- | -- | -- |
| Average Basic Shares Outstanding | 246.80K | 15.60K | -- | -- | -- |
| Average Diluted Shares Outstanding | 246.80K | 15.60K | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
